Kite Readies A Second CAR-T For Filing As CD19 Competition Grows

 
• By Mandy Jackson

The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year. 

T Cell lymphocyte with receptors for cancer cell immunotherapy research 3D render
Kite will soon seek approval for its second T-cell therapy. • Source: Shutterstock

More from Clinical Trials

More from R&D